On the public citation graph
Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach
0 signed · 83 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.291.16.1972openalex-snapshot
HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
inferredcites →https://doi.org/10.1002/path.1313openalex-snapshot
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres
inferredcites →https://doi.org/10.1016/j.ejca.2009.12.014openalex-snapshot
Estimates of cancer incidence and mortality in Europe in 2008
inferredcites →https://doi.org/10.1038/74704openalex-snapshot
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
inferredcites →https://doi.org/10.1038/labinvest.3780204openalex-snapshot
Validation of Tissue Microarray Technology in Breast Carcinoma
inferredcites →https://doi.org/10.1038/modpathol.3800774openalex-snapshot
Standardization of HER2 testing: results of an international proficiency-testing ring study
inferredcites →https://doi.org/10.1038/modpathol.3880440openalex-snapshot
HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization
inferredcites →https://doi.org/10.1056/nejm200103153441101openalex-snapshot
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
inferredcites →https://doi.org/10.1056/nejmoa052122openalex-snapshot
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa052306openalex-snapshot
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa054504openalex-snapshot
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
inferredcites →https://doi.org/10.1056/nejmoa064320openalex-snapshot
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
inferredcites →https://doi.org/10.1093/annonc/mdl498openalex-snapshot
Estimates of the cancer incidence and mortality in Europe in 2006
inferredcites →https://doi.org/10.1093/jnci/90.18.1346openalex-snapshot
erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
inferredcites →https://doi.org/10.1093/jnci/94.11.852openalex-snapshot
Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience
inferredcites →https://doi.org/10.1097/pas.0b013e3181d96231openalex-snapshot
Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma
inferredcites →https://doi.org/10.1136/jcp.2006.040287openalex-snapshot
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas
inferredcites →https://doi.org/10.1136/jcp.2007.053892openalex-snapshot
Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas
inferredcites →https://doi.org/10.1200/jco.1996.14.10.2702openalex-snapshot
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
inferredcites →https://doi.org/10.1200/jco.1998.16.2.462openalex-snapshot
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.
inferredcites →https://doi.org/10.1200/jco.2005.03.4744openalex-snapshot
HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
inferredcites →https://doi.org/10.1200/jco.2006.09.2775openalex-snapshot
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2008.16.2578openalex-snapshot
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
inferredcites →https://doi.org/10.1309/4ncm-qj9w-qm0j-6qjeopenalex-snapshot
A Formalin-Fixed, Paraffin-Processed Cell Line Standard for Quality Control of Immunohistochemical Assay of HER-2/neu Expression in Breast Cancer
inferredcites →https://doi.org/10.1309/97wn-w6ux-xjwt-02h2openalex-snapshot
Evaluation of HER-2/neu Immunohistochemical Assay Sensitivity and Scoring on Formalin-Fixed and Paraffin-Processed Cell Lines and Breast Tumors
inferredcites →https://doi.org/10.1309/ajcpsdg53beancyeopenalex-snapshot
Determination ofHER2Amplification by In Situ Hybridization
inferredcites →https://doi.org/10.3816/cbc.2004.n.011openalex-snapshot
HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues
inferredcites →https://doi.org/10.5858/2008-132-61-htiapsopenalex-snapshot
HER2 Testing in a Population-Based Study of Patients With Metastatic Breast Cancer Treated With Trastuzumab
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1001/jama.2015.17463openalex-snapshot
ERBB2 (HER2)Testing in Breast Cancer
inferred← citeshttps://doi.org/10.1002/hon.2279openalex-snapshot
Acute myeloid leukaemia: expression of MYC protein and its association with cytogenetic risk profile and overall survival
inferred← citeshttps://doi.org/10.1007/s00428-020-02768-xopenalex-snapshot
Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
inferred← citeshttps://doi.org/10.1007/s10549-014-2922-xopenalex-snapshot
HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics
inferred← citeshttps://doi.org/10.1007/s10549-015-3444-xopenalex-snapshot
Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
inferred← citeshttps://doi.org/10.1007/s10549-017-4125-8openalex-snapshot
FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis
inferred← citeshttps://doi.org/10.1007/s10549-020-05532-6openalex-snapshot
MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes
inferred← citeshttps://doi.org/10.1007/s10549-021-06208-5openalex-snapshot
HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines
inferred← citeshttps://doi.org/10.1007/s10549-023-06860-zopenalex-snapshot
Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization
inferred← citeshttps://doi.org/10.1016/b978-0-323-35955-9.00014-3openalex-snapshot
Breast Biomarker Immunocytochemistry
inferred← citeshttps://doi.org/10.1016/j.biopha.2021.112488openalex-snapshot
Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.103174openalex-snapshot
Breast cancer, screening and diagnostic tools: All you need to know
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2022.103883openalex-snapshot
HER2-low breast cancer: Novel detections and treatment advances
inferred← citeshttps://doi.org/10.1016/j.ejca.2014.01.010openalex-snapshot
Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study
inferred← citeshttps://doi.org/10.1016/j.esmorw.2026.100702openalex-snapshot
Multi-site validation of an AI-based biomarker test for determining ER, PR, and HER2 status from H&E-stained breast cancer slides
inferred← citeshttps://doi.org/10.1016/j.prp.2018.10.015openalex-snapshot
Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer
inferred← citeshttps://doi.org/10.1016/j.suronc.2018.05.002openalex-snapshot
High snail expression predicts a poor prognosis in breast invasive ductal carcinoma patients with HER2/EGFR-positive subtypes
inferred← citeshttps://doi.org/10.1016/s1470-2045(18)30570-9openalex-snapshot
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
inferred← citeshttps://doi.org/10.1038/modpathol.2013.103openalex-snapshot
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
inferred← citeshttps://doi.org/10.1038/s41379-020-0636-7openalex-snapshot
A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors
inferred← citeshttps://doi.org/10.1038/s41746-025-01471-yopenalex-snapshot
Convergence of evolving artificial intelligence and machine learning techniques in precision oncology
inferred← citeshttps://doi.org/10.1080/10543406.2013.856018openalex-snapshot
Decision Rules for Subgroup Selection Based on a Predictive Biomarker
inferred← citeshttps://doi.org/10.1093/annonc/mds599openalex-snapshot
Reliability of core needle biopsy for determining ER and HER2 status in breast cancer
inferred← citeshttps://doi.org/10.1093/jnci/djv136openalex-snapshot
Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer
inferred← citeshttps://doi.org/10.1093/nar/gkt845openalex-snapshot
Identifying subgroup markers in heterogeneous populations
inferred← citeshttps://doi.org/10.1097/pai.0000000000000090openalex-snapshot
Evaluation of HER2 Protein Expression Using 2 New Monoclonal Antibodies
inferred← citeshttps://doi.org/10.1097/pai.0000000000000646openalex-snapshot
Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma
inferred← citeshttps://doi.org/10.1111/pin.13288openalex-snapshot
Methods for preparing tissue microarray slides using xenografts with different levels of HER2 expression to standardize HER2 detection
inferred← citeshttps://doi.org/10.1155/2013/368731openalex-snapshot
Comparison of FluorescenceIn SituHybridization and ChromogenicIn SituHybridization for Low and High ThroughputHER2Genetic Testing
inferred← citeshttps://doi.org/10.1177/0300985813510532openalex-snapshot
Veterinary and Human Biobanking Practices
inferred← citeshttps://doi.org/10.1177/17455057241304654openalex-snapshot
Unlocking breast cancer in Brazilian public health system: Using tissue microarray for accurate immunohistochemical evaluation with limitations in subtyping
inferred← citeshttps://doi.org/10.1186/bcr3606openalex-snapshot
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
inferred← citeshttps://doi.org/10.1200/jco.2014.55.6092openalex-snapshot
Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study
inferred← citeshttps://doi.org/10.1245/s10434-023-14439-7openalex-snapshot
Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
inferred← citeshttps://doi.org/10.1309/ajcp4a7ktayhzsoeopenalex-snapshot
Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer
inferred← citeshttps://doi.org/10.1309/ajcpt41tcbuevdqcopenalex-snapshot
Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1
inferred← citeshttps://doi.org/10.1369/0022155417694869openalex-snapshot
Analytic Response Curves of Clinical Breast Cancer IHC Tests
inferred← citeshttps://doi.org/10.1369/0022155417714208openalex-snapshot
The Importance of Epitope Density in Selecting a Sensitive Positive IHC Control
inferred← citeshttps://doi.org/10.1371/journal.pone.0069098openalex-snapshot
Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas
inferred← citeshttps://doi.org/10.1371/journal.pone.0099131openalex-snapshot
In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
inferred← citeshttps://doi.org/10.1371/journal.pone.0123201openalex-snapshot
Fully Automated Fluorescent in situ Hybridization (FISH) Staining and Digital Analysis of HER2 in Breast Cancer: A Validation Study
inferred← citeshttps://doi.org/10.1373/clinchem.2017.274266openalex-snapshot
Improved Detection of HER2 by a Quasi-Targeted Proteomics Approach Using Aptamer–Peptide Probe and Liquid Chromatography–Tandem Mass Spectrometry
inferred← citeshttps://doi.org/10.1586/14737159.2015.992416openalex-snapshot
HER2 assessment by silverin situhybridization: where are we now?
inferred← citeshttps://doi.org/10.17169/refubium-11828openalex-snapshot
Immunhistochemische Untersuchungen zur Expression von Zellzyklusproteinen in verschiedenen Subgruppen des invasiven Mammakarzinoms
inferred← citeshttps://doi.org/10.2147/bctt.s69416openalex-snapshot
Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
inferred← citeshttps://doi.org/10.29289/2594539420230004openalex-snapshot
Can TILs be associated with prognostic factors and survival rates in breast cancer? A retrospective analysis
inferred← citeshttps://doi.org/10.3390/bios13030396openalex-snapshot
Surface Plasmon Resonance (SPR) Sensor for Cancer Biomarker Detection
inferred← citeshttps://doi.org/10.3748/wjg.v19.i38.6438openalex-snapshot
HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays
inferred← citeshttps://doi.org/10.3791/56686openalex-snapshot
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
inferred← citeshttps://doi.org/10.5603/fhc.2013.0044openalex-snapshot
Application of tissue microarrays for receptor immunohistochemistry in breast carcinoma
inferred← citeshttps://doi.org/10.5858/arpa.2013-0031-oaopenalex-snapshot
Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility
inferred← citeshttps://doi.org/10.5858/arpa.2013-0604-oaopenalex-snapshot
HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation
inferred← citeshttps://doi.org/10.5858/arpa.2017-0330-oaopenalex-snapshot
Quantitative Assessment of Immunohistochemistry Laboratory Performance by Measuring Analytic Response Curves and Limits of Detection
inferred← citeshttps://doi.org/10.58837/chula.the.2017.161openalex-snapshot
Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer
inferred← citeshttps://doi.org/10.7314/apjcp.2013.14.10.6131openalex-snapshot
Determination of HER2 Gene Amplification in Breast Cancer using Dual-color Silver Enhanced in situ Hybridization (dc-SISH) and Comparison with Fluorescence ISH (FISH)
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.